# Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06639256/  
OnCo record `nct06639256` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Test Product HY07121 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.

## Summary

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06639256 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 258 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05. Interventions recorded: Test Product HY07121.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06639256
- Phase: 1/2
- Setting: An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
- Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
- Enrolled: 258

## Sources

- ClinicalTrials.gov NCT06639256: https://clinicaltrials.gov/study/NCT06639256

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06639256.json